Downregulation of Profilin-1 Expression Attenuates Cardiomyocytes Hypertrophy and Apoptosis Induced by Advanced Glycation End Products in H9c2 Cells

Cardiomyocytes hypertrophy and apoptosis induced by advanced glycation end products (AGEs) is the crucial pathological foundation contributing to the onset and development of diabetic cardiomyopathy (DCM). However, the mechanism remains poorly understood. Here, we report that profilin-1 (PFN-1), a well-known actin-binding protein, serves as a potent regulator in AGEs-induced cardiomyocytes hypertrophy and apoptosis. PFN-1 was upregulated in AGEs-treated H9c2 cells, which was associated with increased cardiomyocytes hypertrophy and apoptosis. Silencing PFN-1 expression remarkably attenuated AGEs-induced H9c2 cell hypertrophy and apoptosis. Mechanistically, AGEs increased PFN-1 expression through elevating ROS production and RhoA and ROCK2 expression. Consequently, elevated PFN-1 promoted actin cytoskeleton disorganization. When either ROS production/ROCK activation was blocked or cells were treated with Cytochalasin D (actin depolymerizer), H9c2 cells were protected against AGEs-induced cardiac myocyte abnormalities, concomitantly with downregulated expression of PFN-1 and improved actin cytoskeleton alteration. Collectively, these data suggest that PFN-1 may play an important role in AGEs-induced hypertrophy and apoptosis in H9c2 cells.

[1]  Dafeng Yang,et al.  Profilin-1 contributes to cardiac injury induced by advanced glycation end-products in rats , 2017, Molecular Medicine Reports.

[2]  G. Fu,et al.  Erratum to: The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling , 2016, Journal of Molecular Medicine.

[3]  G. Fu,et al.  The Rho kinase inhibitor, fasudil, ameliorates diabetes-induced cardiac dysfunction by improving calcium clearance and actin remodeling , 2016, Journal of Molecular Medicine.

[4]  J. Liao,et al.  Rho Kinases and Cardiac Remodeling. , 2016, Circulation journal : official journal of the Japanese Circulation Society.

[5]  Dong I. Lee,et al.  Profilin modulates sarcomeric organization and mediates cardiomyocyte hypertrophy , 2016, Cardiovascular research.

[6]  H. Shimokawa,et al.  RhoA/Rho-Kinase in the Cardiovascular System. , 2016, Circulation research.

[7]  N. Kellow,et al.  Effect of diet-derived advanced glycation end products on inflammation. , 2015, Nutrition reviews.

[8]  Yawei Xu,et al.  SIRT1 suppresses cardiomyocyte apoptosis in diabetic cardiomyopathy: An insight into endoplasmic reticulum stress response mechanism. , 2015, International journal of cardiology.

[9]  S. Yamagishi,et al.  Evaluation of tissue accumulation levels of advanced glycation end products by skin autofluorescence: A novel marker of vascular complications in high-risk patients for cardiovascular disease. , 2015, International journal of cardiology.

[10]  Nirmal Singh,et al.  Advanced Glycation End Products and Diabetic Complications , 2014, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[11]  J. van der Velden,et al.  The physiological role of cardiac cytoskeleton and its alterations in heart failure. , 2014, Biochimica et biophysica acta.

[12]  E. Abel,et al.  Molecular mechanisms of diabetic cardiomyopathy , 2014, Diabetologia.

[13]  V. Monnier,et al.  Impaired left ventricular function and myocardial blood flow reserve in patients with long-term type 1 diabetes and no significant coronary artery disease: Associations with protein glycation , 2014, Diabetes & vascular disease research.

[14]  Tianlun Yang,et al.  The role of profilin-1 in endothelial cell injury induced by advanced glycation end products (AGEs) , 2013, Cardiovascular Diabetology.

[15]  G. Hageman,et al.  Mild Oxidative Damage in the Diabetic Rat Heart Is Attenuated by Glyoxalase-1 Overexpression , 2013, International journal of molecular sciences.

[16]  Yan Wang,et al.  Profilin-1 promotes the development of hypertension-induced cardiac hypertrophy , 2013, Journal of hypertension.

[17]  Tzong-Ming Shieh,et al.  Cell Hypertrophy and MEK/ERK Phosphorylation are Regulated by Glyceraldehyde-Derived AGEs in Cardiomyocyte H9c2 Cells , 2013, Cell Biochemistry and Biophysics.

[18]  K. Macleod,et al.  Diabetes-induced increased oxidative stress in cardiomyocytes is sustained by a positive feedback loop involving Rho kinase and PKCβ2. , 2012, American journal of physiology. Heart and circulatory physiology.

[19]  M. Zembala,et al.  Advanced glycation end product accumulation in the cardiomyocytes of heart failure patients with and without diabetes. , 2012, Annals of transplantation.

[20]  S. Yuda,et al.  Diabetic cardiomyopathy: pathophysiology and clinical features , 2012, Heart Failure Reviews.

[21]  K. Kaibuchi,et al.  Rho-Kinase/ROCK: A Key Regulator of the Cytoskeleton and Cell Polarity , 2010, Cytoskeleton.

[22]  R. Webb,et al.  RhoA/Rho-kinase and vascular diseases: what is the link? , 2010, Cellular and Molecular Life Sciences.

[23]  A. Heagerty,et al.  Diabetic cardiomyopathy--a distinct disease? , 2009, Best practice & research. Clinical endocrinology & metabolism.

[24]  H. Krum,et al.  Letter by Connelly et al regarding article, "Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension". , 2008, Circulation.

[25]  J. McNeill,et al.  Acute inhibition of Rho-kinase improves cardiac contractile function in streptozotocin-diabetic rats. , 2007, Cardiovascular research.

[26]  Shi-Yan Li,et al.  Advanced glycation endproduct induces ROS accumulation, apoptosis, MAP kinase activation and nuclear O-GlcNAcylation in human cardiac myocytes. , 2007, Life sciences.

[27]  S. Javadov,et al.  Essential role of Rho/ROCK-dependent processes and actin dynamics in mediating leptin-induced hypertrophy in rat neonatal ventricular myocytes. , 2006, Cardiovascular research.

[28]  G. Cooper,et al.  Cytoskeletal networks and the regulation of cardiac contractility: microtubules, hypertrophy, and cardiac dysfunction. , 2006, American journal of physiology. Heart and circulatory physiology.

[29]  H. Katus,et al.  The sarcomeric Z-disc: a nodal point in signalling and disease , 2006, Journal of Molecular Medicine.

[30]  J. Uribarri,et al.  Diet‐Derived Advanced Glycation End Products Are Major Contributors to the Body's AGE Pool and Induce Inflammation in Healthy Subjects , 2005, Annals of the New York Academy of Sciences.

[31]  M. Cooper,et al.  Importance of advanced glycation end products in diabetes-associated cardiovascular and renal disease. , 2004, American journal of hypertension.

[32]  W. Witke The role of profilin complexes in cell motility and other cellular processes. , 2004, Trends in cell biology.

[33]  J. Schaper,et al.  The Cytoskeleton and Related Proteins in the Human Failing Heart , 2000, Heart Failure Reviews.

[34]  J. Schaper,et al.  The role of the cytoskeleton in heart failure. , 2000, Cardiovascular research.

[35]  J. Squire,et al.  Architecture and function in the muscle sarcomere. , 1997, Current opinion in structural biology.

[36]  C. Spadaccio,et al.  Basic and Clinical Research Against Advanced Glycation End Products (AGEs): New Compounds to Tackle Cardiovascular Disease and Diabetic Complications. , 2015, Recent advances in cardiovascular drug discovery.

[37]  T. Murohara,et al.  Diabetes-related heart failure. , 2014, Circulation journal : official journal of the Japanese Circulation Society.

[38]  Sreedhar Bodiga,et al.  Advanced glycation end products: role in pathology of diabetic cardiomyopathy , 2013, Heart Failure Reviews.

[39]  Yan Wang,et al.  Effect of ouabain on myocardial ultrastructure and cytoskeleton during the development of ventricular hypertrophy , 2011, Heart and Vessels.